Filip Hanak

This study identifies the N-terminal catalytic domain of ACE as the primary site for endogenous opioid peptide degradation in brain tissue and shows that inhibiting this domain reduces opioid degradation.

The paper identifies ACE inhibitors that enhance endogenous opioid signaling by reducing enkephalin degradation, showing analgesic effects in vivo.

This paper develops PSA inhibitors to prolong enkephalin stability and reduce pain, showing analgesic effects in vivo and confirming their mechanism through pharmacokinetics and modeling.